Reports Q3 revenue $80.2M, consensus $80.55M. “We are proud to report another strong quarter, marking two years of continuous growth for KIMMTRAK and another quarter of positive net income,” said Bahija Jallal, Immunocore’s (IMCR) Chief Executive Officer. “We are also making significant strides in advancing our broad pipeline – with brenetafusp in oncology, the HIV functional cure trial in infectious diseases, and in autoimmune diseases with tissue-targeted programs for type 1 diabetes and dermatologic diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore initiated with a Sell at UBS
- Immunocore price target lowered to $74 from $80 at Morgan Stanley
- Immunocore downgraded to Neutral from Buy at Guggenheim
- Immunocore downgraded at Guggenheim with trajectory for Kimmtrak appreciated
- Immunocore presents Phase 1 data of brenetafusp in ovarian cancer